| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Net revenue | 13,888 | 18,452 | 16,574 | |
| Cost of goods sold | 4,702 | 5,646 | 4,589 | |
| Gross profit | 9,186 | 12,806 | 11,985 | |
| Selling and marketing | 5,322 | 5,194 | 5,659 | |
| General and administrative | 4,924 | 4,109 | 5,125 | |
| Research and development | 0 | 162 | 426 | |
| Amortization of intangible assets | 444 | 920 | 921 | |
| Restructuring costs | 0 | - | 784 | |
| Total operating expenses | 10,690 | 10,385 | 12,915 | |
| Loss from operations | -1,504 | 2,421 | -930 | |
| Other income, net | 201 | 36 | 542 | |
| Interest expense | 516 | 900 | 994 | |
| Derivative warrant liabilities gain | 3,784 | 2,261 | 2,880 | |
| Income from continuing operations before income tax expense | 1,965 | 3,818 | 1,498 | |
| Income tax expense | 0 | -122 | 405 | |
| Net income from continuing operations | 1,965 | 3,940 | 1,093 | |
| Net income (loss) from discontinued operations, net of tax | - | - | 381 | |
| Net income from discontinued operations, net of tax | 0 | 54 | - | |
| Net income | 1,965 | 3,994 | 1,474 | |
| Basic - net income (in dollars per share) | 0.21 | 0.65 | 0.24 | |
| Basic weighted-average common shares outstanding (note 17) (in shares) | 9,441,073 | 6,134,634 | 6,068,019 | |
| Diluted - net loss (in dollars per share) | -0.08 | 0.21 | -0.15 | |
| Diluted weighted-average common shares outstanding (note 17) (in shares) | 19,476,635 | 8,204,453 | 9,099,601 | |
AYTU BIOPHARMA, INC (AYTU)
AYTU BIOPHARMA, INC (AYTU)